Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

Veradermics, Incorporated shares surged Monday, after the company reported its experimental oral hair-loss treatment, VDPHL01, hit all main and key secondary endpoints in a Phase 2/3 study of men with mild-to-moderate pattern hair loss. The Phase 2/3 trial—a mid- to late-stage human study—is designed to assess safety and efficacy ahead of a potential approval filing.